Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma

Urothelial Carcinoma Clinical Trial

Official title:

GU-114: Overcoming Checkpoint Inhibitor Resistance With Epigenetic Therapy in Urothelial Cancer

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT03179943
• Other study ID #: GU-114
• Secondary ID: SU2C-AACR-CT08-1
• Status: Active, not recruiting
• Phase: Phase 2
• Start date: November 27, 2017
• Est. completion date: July 2022

Study information

• Verified date: November 2021
• Source: Fox Chase Cancer Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a single arm Phase II study with a safety run-in to identify the recommended phase II dose of the combination therapy of atezolizumab and guadecitabine. Patients with recurrent/advanced urothelial carcinoma (stage IV) who had previously progressed on check-point inhibitor therapy with PD-1 or PD-L1 targeting agents are eligible for this study. After a dose that is safe and tolerable has been established, a dose expansion phase (Phase II) will begin. This study will enroll a total of 4 to 53 patients depending upon the number of patients treated in the safety run-in phase and the number of subjects replaced during the phase II portion.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 21
• Est. completion date: July 2022
• Est. primary completion date: July 12, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Patients must have histologically confirmed urothelial carcinoma that is advanced or metastatic.

2. Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. 1.1 and = 1 site safe for biopsy.

3. Patient must agree to provide fresh biopsy specimens and peripheral blood samples at the time of screening and during the study.

4. Patients must have received or be ineligible for platinum based chemotherapy and must have received at least one line of therapy with a PD-L1 or PD-1 targeting agent.

5. Age > 18 years.

6. ECOG performance status = 2

7. Life expectancy = 12 weeks

8. Patients must have normal organ and marrow function as defined below

• Leukocytes > 3,000/mcL

• Absolute neutrophil count > 1,500/mcL

• Platelets > 100,000/mcL

• Hemoglobin > 9 g/dl (blood transfusion is allowed to meet the eligibility criteria as long as post transfusion hemoglobin is maintained at =9.0 g/dL for 7 days or longer)

• Total bilirubin = 2.5 x institutional upper limit of normal (ULN).

• AST/ALT (SGOT/SGPT) < 2.5 times institutional normal limits unless liver metastases are present in which case AST and ALT must be = 5 x IULN.

• Creatinine within normal institutional limits OR

• Creatinine clearance > 30 Ml/min (Cockcroft-Gault formula or measured with 24h urine)

• INR or PTT/PT = 1.5 ULN unless patient is on stable therapeutic dose of warfarin

9. Ability to understand and willingness to sign a written informed consent and HIPAA consent document

10. Women of child bearing potential and men must agree to remain abstinent or use adequate contraception (failure rate <1%) for the duration of study and for 90 days after the completion of the therapy.

Exclusion Criteria:

1. Patients who have had anti-cancer therapy within 2 weeks prior to entering the study.

2. Patients receiving any other investigational agents

3. Patients with active or untreated CNS disease. Patients previously treated for CNS disease must be asymptomatic and must not be using steroids for at least 4 weeks prior to starting the study treatment.

4. Patients with active auto-immune disease requiring immunosuppressive medication.

5. Patients treated with systemic immunostimulatory agents (such as interferons, IL 12) within 6 weeks of the start of the treatment or 5 half-lives of the drug, whichever is shorter.

6. Treatment with systemic corticosteroids within 2 weeks prior to the start of the treatment. Patients that require inhaled or low-dose corticosteroids for COPD or asthma, mineralocorticoids are allowed.

7. Patients with active malignancies in addition to urothelial carcinoma.

8. Patients with prior treatment with hypomethylating agents.

9. History of leptomeningeal disease

10. Prior allogeneic stem cell or solid organ transplant.

11. Uncontrolled effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently)

12. Uncontrolled symptomatic hypercalcemia (>1.5mmol/L ionized calcium or calcium > 12mg/dl or corrected serum calcium > ULN)

13. Mean QT interval corrected for heart rate (QTc) = 470ms calculated from 3 ECGs using Frediricia's correction.

14. Any prior Grade =3 immune-related adverse event (irAE) while receiving any previous immunotherapy agent, or any unresolved irAE >Grade 1 except for endocrine AEs managed with replacement therapy. Any other AEs unresolved toxicities grade 2 or more from previous anti-cancer therapy, except alopecia, peripheral neuropathy or non-clinically significant lab abnormalities.

15. Receipt of therapeutic oral or IV antibiotics within 2 weeks prior to the start of the study treatment.

16. Active or prior documented inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis)

17. History of severe allergic, anaphylactic or hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins.

18. History of idiopathic pulmonary fibrosis, organizing pneumonia (e.g. bronchiolitis obliterations), drug-induced pneumonitis or idiopathic pneumonitis or evidence of interstitial lung disease or active non-infectious pneumonitis.

19. Active tuberculosis

20. Known hypersensitivity to Chinese hamster ovary cell products or any of the study drugs.

21. Administration of a live, attenuated vaccine within 4 weeks of the start of treatment or anticipation that such a live, attenuated vaccine will be required during the study.

22. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

23. Known HIV-positive patients on combination antiretroviral therapy are ineligible.

24. Known history of HBV or HCV infection.

25. Pregnant or breast feeding.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Transitional Cell
• Urothelial Carcinoma

Intervention

Drug:
• Atezolizumab
Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.
• Guadecitabine
Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles

Locations

Country	Name	City	State
United States	Johns Hopkins University School of Medicine	Baltimore	Maryland
United States	USC Norris Hospital and Clinics	Los Angeles	California
United States	Fox Chase Cancer Center	Philadelphia	Pennsylvania

Sponsors (3)

Lead Sponsor	Collaborator
Fox Chase Cancer Center	Stand Up To Cancer, Van Andel Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Maximum tolerated dose of Guadecitabine in combination of Atezolizumab in safety run-in phase	Dose de-escalation study based on standard 3+3 design will be conducted to test two dose levels of guadecitabine: 45mg/m2 and 36mg/m2 to determine MTD	2-3 months
Primary	Objective Response Rate (RECIST v 1.1) in Phase II		2 years
Secondary	Overall Survival		2 years
Secondary	Progression Free Survival		2 years